R-ISS (Multiple Myeloma)

Revised International Staging System — β2-microglobulin, albumin, LDH and FISH cytogenetics
Serum β2-microglobulin (mg/L)
Serum albumin (g/dL)
Serum LDH
High-risk FISH cytogenetics — del(17p), t(4;14) or t(14;16)
Enter β2-microglobulin and albumin to calculate

About this score

When to use

Stages newly diagnosed multiple myeloma by combining the ISS (β2-microglobulin and albumin) with serum LDH and high-risk FISH cytogenetics — del(17p), t(4;14), t(14;16). ⁦[1]⁩

Pearls and pitfalls

In the IMWG report, 5-year overall survival was 82%, 62% and 40% for R-ISS I, II and III. ⁦[1]⁩
Summarised from the numbered sources under Evidence. Check the source before relying on a statement.
Evidence
[1] Original publication
Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for multiple myeloma: a report from the International Myeloma Working Group. Combined the ISS (β2-microglobulin and albumin) with serum LDH and high-risk FISH cytogenetics [del(17p), t(4;14), t(14;16)]; 5-year overall survival was 82%, 62% and 40% for R-ISS I, II and III.
Journal of Clinical Oncology, 2015
Open source
Last reviewed: 2026-10
Report an error in this calculator
MedScore is an educational and clinical decision-support tool. It does not provide a diagnosis, a treatment, or a drug-dosing recommendation, and it does not replace clinical judgement or local guidelines. Confirm every result against the original source before acting on it. The treating clinician remains responsible for all decisions.
Support the developer
MedScore is free on the web and made by a medical student. If it helps you, you can support its development.
Support MedScore